CABOSEQ: The efficacy of cabozantinib post up-front immuno-oncology combinations in patients with advanced renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).Vishal Navani, Daniel Yick Chin Heng, Toni K. Choueiri et al.|Journal of Clinical Oncology|2022Cited by 5
Efficacy of first-line (1L) immunotherapy (IO)-based regimens in patients with sarcomatoid and/or rhabdoid (S/R) metastatic non-clear cell renal cell carcinoma (nccRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).Chris Labaki, Toni K. Choueiri, Ziad Bakouny et al.|Journal of Clinical Oncology|2023Cited by 4
Outcomes of patients with brain metastases from renal cell carcinoma treated with first-line therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).Kosuke Takemura, Daniel Yick Chin Heng, Audreylie Lemelin et al.|Journal of Clinical Oncology|2023Cited by 4
Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).Matthew Scott Ernst, Daniel Yick Chin Heng, Vishal Navani et al.|Journal of Clinical Oncology|2022Cited by 3
First-line therapy for metastatic renal cell carcinoma with pancreatic metastases: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).Eduard Roussel, Vishal Navani, Lisa Kinget et al.|Journal of Clinical Oncology|2022Cited by 3